{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:39:24Z","timestamp":1792762764929,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.trre.2026.101037","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T04:00:01Z","timestamp":1780718401000},"page":"101037","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incretin therapy and transplant readiness: Distinguishing BMI-based access from physiologic reserve in solid organ transplantation"],"prefix":"10.1016","volume":"40","author":[{"given":"Lucas Maciel de Almeida","family":"Corr\u00eaa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiggi Kevin Virgino","family":"Brand\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan Roberth Delmiro","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla Cristina Silva","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela Wander","family":"Fossati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara Reis Gomes de Mello","family":"Queiroz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana Glazer","family":"Hernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2026.101037_bb0005","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/j.ajt.2025.05.033","article-title":"Practices in the management of kidney transplant candidates and recipients with obesity: a survey of United States transplant programs","volume":"25","author":"Puttarajappa","year":"2025","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2026.101037_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/20543581261434826","article-title":"Five things to know about obesity in kidney transplant candidates","volume":"13","author":"Zahran","year":"2026","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.trre.2026.101037_bb0015","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1097\/TP.0000000000005070","article-title":"Successful implementation of a multidisciplinary weight loss program including GLP1 receptor agonists for liver transplant candidates with high body mass index","volume":"108","author":"Gonzalez","year":"2024","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2026.101037_bb0020","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2026.101037_bb0025","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2026.101037_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/frtra.2025.1623096","article-title":"Elective semaglutide prescription enabled waitlisting and transplantation of otherwise ineligible obese renal transplant candidates","volume":"4","author":"Navaux","year":"2025","journal-title":"Front Transplant"},{"key":"10.1016\/j.trre.2026.101037_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.70344","article-title":"Bridging the gap to waitlist activation: semaglutide\u2019s weight loss efficacy and safety in patients with obesity on dialysis seeking kidney transplantation","volume":"39","author":"Wade","year":"2025","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2026.101037_bb0040","article-title":"Obesity treatment as a bridge to solid organ transplantation: a comparison of bariatric surgery to medical therapy","volume":"16","author":"Roddy","year":"2025","journal-title":"Obes Pillars"},{"key":"10.1016\/j.trre.2026.101037_bb0045","doi-asserted-by":"crossref","DOI":"10.1177\/20543581241300777","article-title":"Physical frailty and functional status in kidney transplantation: a systematic review","volume":"11","author":"Karnabi","year":"2024","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.trre.2026.101037_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2025.100969","article-title":"A systematic review of frailty changes following solid organ transplantation: is it all about the frailty tool?","volume":"40","author":"Li","year":"2026","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2026.101037_bb0055","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/S2213-8587(24)00371-1","article-title":"GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study","volume":"13","author":"Orandi","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.trre.2026.101037_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2025.100965","article-title":"Impact of donor-recipient size mismatch on post-transplant outcomes in kidney transplant recipients: a systematic review","volume":"39","author":"Asif","year":"2025","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2026.101037_bb0065","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ajt.2023.11.002","article-title":"Abdominal CT measurements of body composition and waitlist mortality in kidney transplant candidates","volume":"24","author":"Quint","year":"2024","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2026.101037_bb0070","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4065\/mcp.2010.0336","article-title":"The obesity paradox and mortality associated with surrogates of body size and muscle mass in patients receiving hemodialysis","volume":"85","author":"Kalantar-Zadeh","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.trre.2026.101037_bb0075","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1111\/ajt.12762","article-title":"Frailty predicts wait-list mortality in liver transplant candidates","volume":"14","author":"Lai","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2026.101037_bb0080","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cgh.2011.08.028","article-title":"Muscle wasting is associated with mortality in patients with cirrhosis","volume":"10","author":"Montano-Loza","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.trre.2026.101037_bb0085","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1001\/jamasurg.2019.2845","article-title":"Association between liver transplant wait-list mortality and frailty based on body mass index","volume":"154","author":"Haugen","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.trre.2026.101037_bb0090","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001725","article-title":"Cardiorespiratory fitness from cardiopulmonary exercise testing is a comprehensive risk-stratifying tool in liver transplant candidates","volume":"10","author":"Hughes","year":"2024","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2026.101037_bb0095","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/ajt.15198","article-title":"Report from the American Society of Transplantation on frailty in solid organ transplantation","volume":"19","author":"Kobashigawa","year":"2019","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2026.101037_bb0100","first-page":"173","article-title":"Comparative analysis of efficacy and safety of the glucagon-like-peptide-1 receptor agonists tirzepatide and semaglutide in solid-organ transplant recipients","volume":"24","author":"El Khatib","year":"2026","journal-title":"Exp Clin Transplant"},{"key":"10.1016\/j.trre.2026.101037_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2026.101003","article-title":"Tirzepatide in solid organ transplant recipients: early real-world signals of efficacy and safety-a narrative review","volume":"40","author":"Corr\u00eaa","year":"2026","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2026.101037_bb0110","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfag105","article-title":"Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis","volume":"19","author":"Kanbay","year":"2026","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.trre.2026.101037_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2025.100958","article-title":"The impact of standard- versus reduced-dose tacrolimus exposure on clinical outcomes in adult kidney transplant recipients: a systematic review and meta-analysis","volume":"39","author":"Udomkarnjananun","year":"2025","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2026.101037_bb0120","article-title":"The etiology of reduced muscle mass with surgical and pharmacological weight loss and the identification of potential countermeasures","volume":"17","author":"Faria","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.trre.2026.101037_bb0125","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2215\/CJN.0000000604","article-title":"Weight loss intentionality and frailty are associated with pre-kidney transplant outcomes","volume":"20","author":"Ghildayal","year":"2025","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2026.101037_bb0130","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1186\/s40001-026-03851-w","article-title":"Pre-transplant physical performance, muscle quality, and body composition as predictors of post-liver transplant outcomes: a retrospective cohort study","volume":"31","author":"Fotros","year":"2026","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.trre.2026.101037_bb0135","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s13300-020-00786-1","article-title":"A retrospective study of glucagon-like peptide 1 receptor agonists for the management of diabetes after transplantation","volume":"11","author":"Thangavelu","year":"2020","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.trre.2026.101037_bb0140","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15401","article-title":"Cardio-renal-metabolic outcomes associated with the use of GLP-1 receptor agonists after heart transplantation","volume":"38","author":"Donald","year":"2024","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2026.101037_bb0145","doi-asserted-by":"crossref","first-page":"630","DOI":"10.2337\/ds25-0031","article-title":"Impact of glucagon-like peptide 1 receptor agonists on tacrolimus dose-to-concentration ratios in solid organ transplantation","volume":"38","author":"Sweiss","year":"2025","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.trre.2026.101037_bb0150","article-title":"The role of sarcopenia and body composition in lung transplant candidates: a review","volume":"17","author":"Aher","year":"2025","journal-title":"Cureus"},{"key":"10.1016\/j.trre.2026.101037_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2024.102364","article-title":"Impact of pre-existing frailty on survival outcomes in solid-organ transplant candidates and recipients: a meta-analysis","volume":"99","author":"Geng","year":"2024","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.trre.2026.101037_bb0160","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/jgh3.12702","article-title":"Association of physiological reserve measures with adverse outcomes following liver transplantation","volume":"6","author":"Kimber","year":"2022","journal-title":"JGH Open"},{"key":"10.1016\/j.trre.2026.101037_bb0165","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.70205","article-title":"Relationships between nutrition risk and frailty in candidates for lung transplant","volume":"39","author":"Stewart","year":"2025","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2026.101037_bb0170","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation","volume":"40","author":"Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2026.101037_bb0175","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.tips.2025.08.013","article-title":"Can GLP-1RAs redefine transplantation standard of care?","volume":"46","author":"Almalki","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.trre.2026.101037_bb0180","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the obesity medicine association, and the Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.trre.2026.101037_bb0185","doi-asserted-by":"crossref","DOI":"10.7326\/ANNALS-25-00478","article-title":"Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review","author":"Batsis","year":"2026","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2026.101037_bb0190","doi-asserted-by":"crossref","DOI":"10.1038\/s41366-026-02088-1","article-title":"GLP-1 agonists and changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis","author":"Sawicka-Gutaj","year":"2026","journal-title":"Int J Obes"},{"key":"10.1016\/j.trre.2026.101037_bb0195","article-title":"Body composition changes after bariatric surgery or treatment with GLP-1 receptor agonists","volume":"9","author":"Wang","year":"2026","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.trre.2026.101037_bb0200","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1365162","article-title":"Predictors of effectiveness of glucagon-like peptide-1 receptor agonist therapy in patients with type 2 diabetes and obesity","volume":"2019","author":"Babenko","year":"2019","journal-title":"J Diabetes Res"},{"key":"10.1016\/j.trre.2026.101037_bb0205","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.trre.2026.101037_bb0210","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"American Diabetes Association professional practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2026.101037_bb0215","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1093\/ejendo\/lvaf223","article-title":"Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment","volume":"193","author":"Gonz\u00e1lez-Luis","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.trre.2026.101037_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2025.101681","article-title":"GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies","volume":"51","author":"Scheen","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.trre.2026.101037_bb0225","article-title":"Glucagon like peptide-1 receptor agonists for sarcopenia and muscle wasting disorders: a systematic review of efficacy and mechanisms","author":"Maihemuti","year":"2025","journal-title":"Aging Dis"},{"key":"10.1016\/j.trre.2026.101037_bb0230","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jama.2025.11153","article-title":"Managing adverse effects of incretin-based medications for obesity","volume":"334","author":"Kushner","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2026.101037_bb0235","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.2337\/dc26-S013","article-title":"American Diabetes Association professional practice Committee for Diabetes. 13. Older adults: standards of Care in Diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2026.101037_bb0240","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2026.101037_bb0245","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.bja.2025.04.001","article-title":"Perioperative management of patients taking glucagon-like peptide 1 receptor agonists: Society for Perioperative Assessment and Quality Improvement (SPAQI) multidisciplinary consensus statement","volume":"135","author":"Oprea","year":"2025","journal-title":"Br J Anaesth"},{"key":"10.1016\/j.trre.2026.101037_bb0250","article-title":"Nutritional challenges in post-massive weight loss body contouring: guidance for plastic surgeons on GLP-1 agonists and sleeve gastrectomy","author":"Mehta","year":"2025","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.trre.2026.101037_bb0255","author":"Joshi"},{"key":"10.1016\/j.trre.2026.101037_bb0260","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2026.101037_bb0265","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2026.101037_bb0270","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2026.101037_bb0275","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X26000479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X26000479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:00:37Z","timestamp":1792760437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X26000479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0955470X26000479"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2026.101037","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incretin therapy and transplant readiness: Distinguishing BMI-based access from physiologic reserve in solid organ transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2026.101037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101037"}}